Dr. Roswell Park, the founder of Roswell Park Cancer Institute (RPCI), was one of the nation's most pre-eminent surgeons and arguably the first to articulate the importance of translational research in a cancer center. His revolutionary model of a "multidisciplinary approach" to cancer with scientists and clinicians working in concert and in consult has become the standard by which all modern-day comprehensive cancer centers are measured.
Decisions made at the time of diagnosis and with recurrent disease demand multidisciplinary input to assure the selection of a "best practice" treatment plan for the patient. RPCI's cancer program is disease-specific, with teams working together to develop a comprehensive, individualized care program for each patient from diagnosis, through treatment and rehabilitation, to discharge and follow-up care.
|
Multidisciplinary Teams |
The faculty of RPCI is organized into disease-specific, multidisciplinary teams, with broad representation from clinical care and research, as well as basic and applied science. These teams of specialists work in common locations known as "Centers", which are conveniently located within the Hospital (see Multidisciplinary Centers, below). |
|---|---|
|
Special Expertise |
Translational Research Investigator-initiated Phase I Clinical Research Studies Immunotherapies: Vaccines and Other New Agents Minimally Invasive Surgery (includes robot-assisted surgery, video-assisted thoracic surgery, radiofrequency ablation, Gamma Knife radiosurgery, brachytherapy, etc.) Photodynamic Therapy and the Development of New Imaging Agents Blood and Marrow Transplant Treatment of Complex Cancers Radiation for Treatment of Head & Neck Cancers Lung Cancer Screening/Early Detection for High-Risk Individuals Pathology Diagnostic Radiology Data Bank and BioRepository Genetics Maxillofacial Prosthetics Pain Management Vitamin D Studies Cancer Health Disparities Research Tobacco Control/Cessation Chemoprevention Studies |
|
General Information |
877.275.7724 (877.ASK.RPCI) |
|---|---|
|
Referring Physician/Self-Referral Line |
800.767.9355 (800. |
|
Location |
|
|
Facility |
RPCI's campus on the Buffalo Niagara Medical Campus includes approximately 1.5 million square feet of space equally distributed between clinical programs and research/education functions. |
|
Travel Assistance |
Travel assistance is coordinated through the Department of Psychosocial Oncology |
|
Lodging |
Lodging may be coordinated through the Departments of Psychosocial Oncology and Case Management, or by the patient/family. Available lodging includes The DoubleTree Club Hotel, which is adjacent to RPCI, and The Kevin Guest House, the nation's first hospitality house, which offers affordable housing to RPCI patients, including BMT patients, and their families. |
Multidisciplinary Centers
All Disease Centers listed below may be contacted by calling 800.767.9355 (800.ROSWELL):
Blood & Marrow Transplant
Breast
Chemotherapy/Infusion
Dental/Maxillofacial
Dermatology
Gastrointestinal
Genitourinary
Gynecology
Head & Neck
Leukemia
Lymphoma
Melanoma
Multiple Myeloma
Neuro-Oncology
Pediatrics
Sarcoma
Thoracic
Hematopoietic Stem Cell Transplant Program
Selected malignant and non-malignant hematologic disorders and solid tumors, including those listed below, are treated with autologous, or allogeneic hematopoietic stem cell transplants utilizing blood, bone marrow or cord blood
Amyloidosis
Aplastic Anemia
Acute Lymphoblastic and Myelogenous Leukemias
Chronic Lymphocytic and Myelogenous Leukemias
Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndromes
Neuroblastoma
Testicular Cancer/Germ Cell Tumors
Immunodeficiency Disorders
Alternative/Complementary Medicine
Prevention research examines behaviors, environmental exposures and genetics as they relate to cancer and treatment outcomes. A major challenge in prevention and control of cancer is to identify those persons who are at greatest risk of developing cancer to help them alter their risk and/or receive adequate screening for early detection. RPCI also works to identify predictors of recurrence after diagnosis and treatment so as to enhance cancer survival and patient quality of life.
A major focus of the program is devoted to research on ways to promote prevention and cessation of tobacco use. Recognized as an NIH-supported Transdisciplinary Tobacco Use Research Center of Excellence, RPCI's Tobacco Control Program focuses on how policy in developing and industrialized societies can lessen tobacco dependence. RPCI also operates the New York State Smokers' Quitline at 1-866-NY-QUITS (1-866-697-8487) and runs local tobacco control initiatives sponsored by the New York State Department of Health.
A concentrated commitment to translational research by building prevention linkages to basic science distinguishes the prevention program at RPCI. To explore scientific leads and develop more effective strategies, prevention experts collaborate with researchers from genetics, biochemistry, pharmacology, toxicology, and immunology.
RPCI clinicians work with primary care doctors, nurses, and other health care professionals in the community to enhance cancer control and screening to track cancer patterns, and to develop clinical interventions for prevention.
A critical resource for the program, the Western New York Data Bank and BioRepository (DBBR) collects and provides de-identified biospecimens and associated epidemiological and clinical data to meet the scientific needs of investigators. With its creation in 2003, the DBBR addresses what researchers across the nation have identified as the single greatest need in translational research access to high-quality biological samples. An extensive data collection and management system is in place to track informed consent, questionnaire collection and follow up, epidemiological questionnaire data, clinical data, biospecimens and their derivatives.
RPCI's Disease-site Research Groups (DSRGs), formed to prioritize clinical trials and the use of research tissues in the DBBR, bring together scientists and clinicians to provide a scientific basis for the treatment of specific cancers and to collaborate and explore new concepts in treatment for these diseases.
The mission of the Office of Cancer Health Disparities Research is to understand, reduce, eliminate and prevent cancer disparities in vulnerable and medically underserved populations and patients through trans-disciplinary research and programs.
Cooperative Group Membership
|
Cooperative Group Membership List |
CALGB RTOG ACOS CTSU GOG COG SWOG NSABP |
|---|---|
|
Activities in Cooperative Group |
RPCI houses the GOG Statistical Office |
|
Average Number of Adult Clinical Trials |
In 2010, RPCI had a total of 700 active clinical research studies. This includes 242 intervention studies and 265 non-intervention studies. During the same CY, RPCI had 66 phase I clinical research studies, and 45 were RPCI-investigator-initiated. |
The collaboration and regular contact between clinicians and scientists encourage translational research and the development of new investigator-driven clinical trials that afford patients a wider range of treatment options, and ultimately lead to better approaches and improved technologies to reduce the cancer burden.
|
No. of Inpatient Beds (Medical/Surgical) |
No. of Admissions |
Average Length of Stay (days) |
No. of New Outpatients |
No. of Oncologists (Medical and Surgical) |
|---|---|---|---|---|
|
121** |
5,156 |
7.1 days |
8,478 |
165 |
*Figures reflect RPCI activity from April 1, 2010 through March 31, 2011.
**Number of beds in service as of 12/31/2012.
| Quick Links |
|
|
About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us
275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0260
Copyright © 2012 National Comprehensive Cancer Network, All Rights Reserved